Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 607 | 89 | 512 |
| Samples | 294 | 54 | 236 |
| Peptides | 255 | 36 | 217 |
Function
ZBTB33 · Zinc finger and BTB domain containing 33
This gene encodes a transcriptional regulator with bimodal DNA-binding specificity, which binds to methylated CGCG and also to the non-methylated consensus KAISO-binding site TCCTGCNA. The protein contains an N-terminal POZ/BTB domain and 3 C-terminal zinc finger motifs. It recruits the N-CoR repressor complex to promote histone deacetylation and the formation of repressive chromatin structures in target gene promoters. It may contribute to the repression of target genes of the Wnt signaling pathway, and may also activate transcription of a subset of target genes by the recruitment of catenin delta-2 (CTNND2). Its interaction with catenin delta-1 (CTNND1) inhibits binding to both methylated and non-methylated DNA. It also interacts directly with the nuclear import receptor Importin-alpha2 (also known as karyopherin alpha2 or RAG cohort 1), which may mediate nuclear import of this protein. Alternatively spliced transcript variants encoding the same protein have been identified.[provided by RefSeq, May 2010].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 255 amino-acid changes on canonical ENST00000557385 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ZBTB33 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ZBTB33 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 4/42 10% | 29/612 5% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Melanoma | 8/210 4% | 35/1899 2% |
| Cervical Carcinoma | 3/35 9% | 4/422 1% |
| Neuroendocrine Tumour | 5/154 3% | 4/577 1% |
| Colorectal Carcinoma | 9/143 6% | 32/3239 1% |
| Gastric Carcinoma | 6/74 8% | 15/1809 1% |
| Bladder Carcinoma | 0/58 0% | 9/956 1% |
| Burkitts Lymphoma | 1/32 3% | 1/196 1% |
| Other Solid Cancers | 0/94 0% | 13/1515 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 9/1390 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Ewings Sarcoma | 2/63 3% | 0/262 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 5/810 1% |
| Plasma Cell Myeloma | 1/44 2% | 1/305 0% |
| Other Sarcomas | 0/69 0% | 4/699 1% |
| Biliary Tract Carcinoma | 0/54 0% | 5/950 1% |
| Ovarian Carcinoma | 0/109 0% | 5/998 0% |
| Glioma | 0/52 0% | 9/2127 0% |
| B-Cell Non-Hodgkins Lymphoma | 4/88 5% | 4/2534 0% |
| Kidney Carcinoma | 0/85 0% | 6/1862 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 8/2550 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 5/1592 0% |
| Head and Neck Carcinoma | 0/85 0% | 5/1574 0% |
| Esophageal Carcinoma | 1/23 4% | 1/769 0% |
| Breast Carcinoma | 0/144 0% | 8/3264 0% |
| Hepatocellular Carcinoma | 1/46 2% | 4/2210 0% |
| B-Lymphoblastic Leukemia | 1/55 2% | 5/2640 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
Mutation Distribution
Where ZBTB33 is mutated · all tissues, split by cell line vs tissue
How many mutations in ZBTB33 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 607 mutations in ZBTB33
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|